You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePargyline
Accession NumberDB01626
TypeSmall Molecule
GroupsApproved
DescriptionA monoamine oxidase inhibitor with antihypertensive properties. [PubChem]
Structure
Thumb
Synonyms
Eutonyl
Eutron
Pargyline
External Identifiers
  • Lopac-P-8013
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
EutonylNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Pargyline hydrochloride
Thumb
  • InChI Key: BCXCABRDBBWWGY-UHFFFAOYSA-N
  • Monoisotopic Mass: 195.08147716
  • Average Mass: 195.689
DBSALT000304
Categories
UNII9MV14S8G3E
CAS number555-57-7
WeightAverage: 159.2276
Monoisotopic: 159.104799421
Chemical FormulaC11H13N
InChI KeyInChIKey=DPWPWRLQFGFJFI-UHFFFAOYSA-N
InChI
InChI=1S/C11H13N/c1-3-9-12(2)10-11-7-5-4-6-8-11/h1,4-8H,9-10H2,2H3
IUPAC Name
benzyl(methyl)(prop-2-yn-1-yl)amine
SMILES
CN(CC#C)CC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylmethylamines. These are compounds containing a phenylmethtylamine moiety, which consists of a phenyl group substituted by an methanamine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylmethylamines
Direct ParentPhenylmethylamines
Alternative Parents
Substituents
  • Phenylmethylamine
  • Benzylamine
  • Aralkylamine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of moderate to severe hypertension.
PharmacodynamicsPargyline is a monoamine oxidase B (MAO-B) inhibitor with antihypertensive properties. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.
Mechanism of actionMAOIs act by inhibiting the activity of monoamine oxidase, thus preventing the breakdown of monoamine neurotransmitters and thereby increasing their availability. There are two isoforms of monoamine oxidase, MAO-A and MAO-B. MAO-A preferentially deaminates serotonin, melatonin, epinephrine and norepinephrine. MAO-B preferentially deaminates phenylethylamine and trace amines. Pargyline functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Catecholamines cause general physiological changes that prepare the body for physical activity (fight-or-flight response). Some typical effects are increases in heart rate, blood pressure, blood glucose levels, and a general reaction of the sympathetic nervous system.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9504
Blood Brain Barrier+0.9568
Caco-2 permeable+0.8188
P-glycoprotein substrateNon-substrate0.6641
P-glycoprotein inhibitor INon-inhibitor0.9864
P-glycoprotein inhibitor IINon-inhibitor0.9357
Renal organic cation transporterNon-inhibitor0.5518
CYP450 2C9 substrateNon-substrate0.8061
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.6977
CYP450 1A2 substrateNon-inhibitor0.7981
CYP450 2C9 inhibitorNon-inhibitor0.9213
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.945
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7826
Ames testNon AMES toxic0.9413
CarcinogenicityNon-carcinogens0.5475
BiodegradationNot ready biodegradable0.9459
Rat acute toxicity2.6935 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7258
hERG inhibition (predictor II)Non-inhibitor0.8819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0998 mg/mLALOGPS
logP2.05ALOGPS
logP2.14ChemAxon
logS-3.2ALOGPS
pKa (Strongest Basic)8.13ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity52.18 m3·mol-1ChemAxon
Polarizability18.78 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (10 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesC02LL01C02KC01
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
3,4-MethylenedioxyamphetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.
3,4-MethylenedioxymethamphetaminePargyline may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Pargyline.
AcarbosePargyline may increase the hypoglycemic activities of Acarbose.
AcebutololAcebutolol may increase the hypotensive activities of Pargyline.
AlbiglutidePargyline may increase the hypoglycemic activities of Albiglutide.
AlfuzosinAlfuzosin may increase the hypotensive activities of Pargyline.
AliskirenPargyline may increase the hypotensive activities of Aliskiren.
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pargyline.
AlogliptinPargyline may increase the hypoglycemic activities of Alogliptin.
AlprenololAlprenolol may increase the hypotensive activities of Pargyline.
AltretamineAltretamine may increase the orthostatic hypotensive activities of Pargyline.
AmbrisentanPargyline may increase the hypotensive activities of Ambrisentan.
AmifostinePargyline may increase the hypotensive activities of Amifostine.
AmineptinePargyline may increase the serotonergic activities of Amineptine.
AmitriptylinePargyline may increase the serotonergic activities of Amitriptyline.
AmlodipineAmlodipine may increase the hypotensive activities of Pargyline.
AmoxapinePargyline may increase the serotonergic activities of Amoxapine.
AmphetaminePargyline may increase the hypertensive activities of Amphetamine.
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Pargyline.
ApraclonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Apraclonidine.
ArbutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Arbutamine.
ArformoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Arformoterol.
AtenololAtenolol may increase the hypotensive activities of Pargyline.
AtomoxetinePargyline may increase the central neurotoxic activities of Atomoxetine.
AtropinePargyline may increase the hypertensive activities of Atropine.
BambuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Bambuterol.
BenazeprilBenazepril may increase the hypotensive activities of Pargyline.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Pargyline.
BenmoxinBenmoxin may increase the hypotensive activities of Pargyline.
BenzphetaminePargyline may increase the hypertensive activities of Benzphetamine.
BepridilBepridil may increase the hypotensive activities of Pargyline.
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Pargyline.
BetaxololBetaxolol may increase the hypotensive activities of Pargyline.
BethanidineBethanidine may increase the hypotensive activities of Pargyline.
BezafibrateThe risk or severity of adverse effects can be increased when Pargyline is combined with Bezafibrate.
BimatoprostBimatoprost may increase the hypotensive activities of Pargyline.
BisoprololBisoprolol may increase the hypotensive activities of Pargyline.
BosentanBosentan may increase the hypotensive activities of Pargyline.
BretyliumBretylium may increase the hypotensive activities of Pargyline.
BrimonidineBrimonidine may increase the antihypertensive activities of Pargyline.
BrimonidineThe risk or severity of adverse effects can be increased when Pargyline is combined with Brimonidine.
BromocriptineThe metabolism of Bromocriptine can be decreased when combined with Pargyline.
BupranololPargyline may increase the hypotensive activities of Bupranolol.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pargyline.
BupropionPargyline may increase the hypertensive activities of Bupropion.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pargyline.
CabergolineThe metabolism of Cabergoline can be decreased when combined with Pargyline.
CanagliflozinPargyline may increase the hypoglycemic activities of Canagliflozin.
CandesartanCandesartan may increase the hypotensive activities of Pargyline.
CandoxatrilCandoxatril may increase the hypotensive activities of Pargyline.
CaptoprilCaptopril may increase the hypotensive activities of Pargyline.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline.
CaroxazoneCaroxazone may increase the hypotensive activities of Pargyline.
CarteololCarteolol may increase the hypotensive activities of Pargyline.
CarvedilolCarvedilol may increase the hypotensive activities of Pargyline.
CeliprololPargyline may increase the hypotensive activities of Celiprolol.
ChlorothiazideChlorothiazide may increase the hypotensive activities of Pargyline.
ChlorphenterminePargyline may increase the hypertensive activities of Chlorphentermine.
ChlorpropamidePargyline may increase the hypoglycemic activities of Chlorpropamide.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Pargyline.
CilazaprilCilazapril may increase the hypotensive activities of Pargyline.
CirazolinePargyline may increase the hypertensive activities of Cirazoline.
CitalopramPargyline may increase the serotonergic activities of Citalopram.
ClemastinePargyline may increase the anticholinergic activities of Clemastine.
ClenbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Clenbuterol.
ClomipraminePargyline may increase the serotonergic activities of Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Pargyline.
CryptenamineCryptenamine may increase the hypotensive activities of Pargyline.
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Pargyline.
CyclothiazideCyclothiazide may increase the hypotensive activities of Pargyline.
CyproheptadinePargyline may increase the anticholinergic activities of Cyproheptadine.
DapagliflozinPargyline may increase the hypoglycemic activities of Dapagliflozin.
DapoxetinePargyline may increase the serotonergic activities of Dapoxetine.
DebrisoquinPargyline may increase the hypotensive activities of Debrisoquin.
DeserpidinePargyline may increase the hypotensive activities of Deserpidine.
DesipraminePargyline may increase the serotonergic activities of Desipramine.
DesvenlafaxinePargyline may increase the serotonergic activities of Desvenlafaxine.
DexmethylphenidatePargyline may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetaminePargyline may increase the hypertensive activities of Dextroamphetamine.
DextromethorphanPargyline may increase the serotonergic activities of Dextromethorphan.
DiazoxideDiazoxide may increase the hypotensive activities of Pargyline.
DiethylpropionPargyline may increase the hypertensive activities of Diethylpropion.
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Pargyline.
DiltiazemDiltiazem may increase the hypotensive activities of Pargyline.
DipivefrinThe risk or severity of adverse effects can be increased when Pargyline is combined with Dipivefrin.
DisopyramidePargyline may increase the hypoglycemic activities of Disopyramide.
DobutamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Dobutamine.
DomperidoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Domperidone.
DorzolamideDorzolamide may increase the hypotensive activities of Pargyline.
DosulepinPargyline may increase the serotonergic activities of Dosulepin.
DoxapramPargyline may increase the hypertensive activities of Doxapram.
DoxazosinDoxazosin may increase the hypotensive activities of Pargyline.
DoxepinPargyline may increase the serotonergic activities of Doxepin.
DoxylaminePargyline may increase the anticholinergic activities of Doxylamine.
DroxidopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Droxidopa.
DulaglutidePargyline may increase the hypoglycemic activities of Dulaglutide.
DuloxetinePargyline may increase the serotonergic activities of Duloxetine.
EfonidipinePargyline may increase the hypotensive activities of Efonidipine.
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pargyline.
EmpagliflozinPargyline may increase the hypoglycemic activities of Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Pargyline.
EnalaprilatPargyline may increase the hypotensive activities of Enalaprilat.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline.
EphedraThe risk or severity of adverse effects can be increased when Pargyline is combined with Ephedra.
EpinephrinePargyline may increase the hypertensive activities of Epinephrine.
EpoprostenolEpoprostenol may increase the hypotensive activities of Pargyline.
EprosartanEprosartan may increase the hypotensive activities of Pargyline.
ErgotaminePargyline may increase the hypertensive activities of Ergotamine.
EscitalopramPargyline may increase the serotonergic activities of Escitalopram.
EsmirtazapinePargyline may increase the serotonergic activities of Esmirtazapine.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pargyline.
EtoperidonePargyline may increase the serotonergic activities of Etoperidone.
ExenatidePargyline may increase the hypoglycemic activities of Exenatide.
FelodipineFelodipine may increase the hypotensive activities of Pargyline.
FenfluraminePargyline may increase the serotonergic activities of Fenfluramine.
FenoldopamFenoldopam may increase the hypotensive activities of Pargyline.
FenoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Fenoterol.
FluoxetinePargyline may increase the serotonergic activities of Fluoxetine.
FluvoxaminePargyline may increase the serotonergic activities of Fluvoxamine.
FormoterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Formoterol.
FosinoprilFosinopril may increase the hypotensive activities of Pargyline.
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Pargyline.
FurazolidoneFurazolidone may increase the hypotensive activities of Pargyline.
GliclazidePargyline may increase the hypoglycemic activities of Gliclazide.
GlimepiridePargyline may increase the hypoglycemic activities of Glimepiride.
GlipizidePargyline may increase the hypoglycemic activities of Glipizide.
GlyburidePargyline may increase the hypoglycemic activities of Glyburide.
GuanabenzGuanabenz may increase the hypotensive activities of Pargyline.
GuanadrelGuanadrel may increase the hypotensive activities of Pargyline.
GuanethidineGuanethidine may increase the hypotensive activities of Pargyline.
GuanfacineGuanfacine may increase the hypotensive activities of Pargyline.
HexamethoniumPargyline may increase the hypotensive activities of Hexamethonium.
HydracarbazineHydracarbazine may increase the hypotensive activities of Pargyline.
HydralazineHydralazine may increase the hypotensive activities of Pargyline.
HydrochlorothiazideHydrochlorothiazide may increase the hypotensive activities of Pargyline.
HydrocodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydrocodone.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Pargyline.
HydromorphoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Hydromorphone.
Hydroxyamphetamine hydrobromidePargyline may increase the hypertensive activities of Hydroxyamphetamine hydrobromide.
IloprostIloprost may increase the hypotensive activities of Pargyline.
ImipraminePargyline may increase the serotonergic activities of Imipramine.
IndacaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Indacaterol.
IndalpinePargyline may increase the serotonergic activities of Indalpine.
IndapamideIndapamide may increase the hypotensive activities of Pargyline.
IndenololPargyline may increase the hypotensive activities of Indenolol.
IndoraminPargyline may increase the hypotensive activities of Indoramin.
Insulin AspartPargyline may increase the hypoglycemic activities of Insulin Aspart.
Insulin DetemirPargyline may increase the hypoglycemic activities of Insulin Detemir.
Insulin GlarginePargyline may increase the hypoglycemic activities of Insulin Glargine.
Insulin GlulisinePargyline may increase the hypoglycemic activities of Insulin Glulisine.
Insulin HumanPargyline may increase the hypoglycemic activities of Insulin Human.
Insulin LisproPargyline may increase the hypoglycemic activities of Insulin Lispro.
IproclozideIproclozide may increase the hypotensive activities of Pargyline.
IproniazidIproniazid may increase the hypotensive activities of Pargyline.
IrbesartanIrbesartan may increase the hypotensive activities of Pargyline.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Pargyline.
IsoetarineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoetarine.
IsomethepteneThe risk or severity of adverse effects can be increased when Pargyline is combined with Isometheptene.
IsoprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline.
IsradipineIsradipine may increase the hypotensive activities of Pargyline.
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pargyline.
LabetalolLabetalol may increase the hypotensive activities of Pargyline.
LacidipinePargyline may increase the hypotensive activities of Lacidipine.
LanreotidePargyline may increase the hypoglycemic activities of Lanreotide.
LatanoprostLatanoprost may increase the hypotensive activities of Pargyline.
LercanidipineLercanidipine may increase the hypotensive activities of Pargyline.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pargyline.
LevomilnacipranPargyline may increase the serotonergic activities of Levomilnacipran.
LevonordefrinPargyline may increase the hypertensive activities of Levonordefrin.
LinezolidThe risk or severity of adverse effects can be increased when Pargyline is combined with Linezolid.
LiraglutidePargyline may increase the hypoglycemic activities of Liraglutide.
LisdexamfetaminePargyline may increase the hypertensive activities of Lisdexamfetamine.
LisinoprilLisinopril may increase the hypotensive activities of Pargyline.
LisurideThe metabolism of Lisuride can be decreased when combined with Pargyline.
LithiumThe risk or severity of adverse effects can be increased when Pargyline is combined with Lithium.
LofexidinePargyline may increase the hypotensive activities of Lofexidine.
LosartanLosartan may increase the hypotensive activities of Pargyline.
Lu AA21004Pargyline may increase the serotonergic activities of Lu AA21004.
MacitentanPargyline may increase the hypotensive activities of Macitentan.
ManidipinePargyline may increase the hypotensive activities of Manidipine.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pargyline.
MebanazineMebanazine may increase the hypotensive activities of Pargyline.
MecamylamineMecamylamine may increase the hypotensive activities of Pargyline.
MecaserminPargyline may increase the hypoglycemic activities of Mecasermin.
MephenterminePargyline may increase the hypertensive activities of Mephentermine.
MequitazinePargyline may increase the anticholinergic activities of Mequitazine.
MetaraminolPargyline may increase the hypertensive activities of Metaraminol.
MetforminPargyline may increase the hypoglycemic activities of Metformin.
MethadoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Methadone.
MethamphetaminePargyline may increase the hypertensive activities of Methamphetamine.
MethoxaminePargyline may increase the hypertensive activities of Methoxamine.
MethyldopaThe risk or severity of adverse effects can be increased when Pargyline is combined with Methyldopa.
MethyldopaMethyldopa may increase the hypotensive activities of Pargyline.
Methylene bluePargyline may increase the serotonergic activities of Methylene blue.
Methylene blueMethylene blue may increase the hypotensive activities of Pargyline.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Pargyline.
MethylphenidatePargyline may increase the hypertensive activities of Methylphenidate.
MetipranololMetipranolol may increase the hypotensive activities of Pargyline.
MetolazoneMetolazone may increase the hypotensive activities of Pargyline.
MetoprololMetoprolol may increase the hypotensive activities of Pargyline.
MianserinPargyline may increase the neurotoxic activities of Mianserin.
MibefradilMibefradil may increase the hypotensive activities of Pargyline.
MidodrinePargyline may increase the hypertensive activities of Midodrine.
MifepristonePargyline may increase the hypoglycemic activities of Mifepristone.
MiglitolPargyline may increase the hypoglycemic activities of Miglitol.
MilnacipranPargyline may increase the serotonergic activities of Milnacipran.
MinaprineMinaprine may increase the hypotensive activities of Pargyline.
MinoxidilMinoxidil may increase the hypotensive activities of Pargyline.
MirtazapinePargyline may increase the central neurotoxic activities of Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Pargyline is combined with Moclobemide.
MoclobemideMoclobemide may increase the hypotensive activities of Pargyline.
MoexiprilMoexipril may increase the hypotensive activities of Pargyline.
MolsidomineMolsidomine may increase the hypotensive activities of Pargyline.
MorphineThe risk or severity of adverse effects can be increased when Pargyline is combined with Morphine.
MoxonidinePargyline may increase the hypotensive activities of Moxonidine.
NadololNadolol may increase the hypotensive activities of Pargyline.
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Pargyline.
NateglinidePargyline may increase the hypoglycemic activities of Nateglinide.
NebivololPargyline may increase the hypotensive activities of Nebivolol.
NialamideNialamide may increase the hypotensive activities of Pargyline.
NicardipineNicardipine may increase the hypotensive activities of Pargyline.
NicorandilPargyline may increase the hypotensive activities of Nicorandil.
NiguldipinePargyline may increase the hypotensive activities of Niguldipine.
NilvadipinePargyline may increase the hypotensive activities of Nilvadipine.
NimodipineNimodipine may increase the hypotensive activities of Pargyline.
NisoldipineNisoldipine may increase the hypotensive activities of Pargyline.
NitrendipineNitrendipine may increase the hypotensive activities of Pargyline.
NitroprussideNitroprusside may increase the hypotensive activities of Pargyline.
NorepinephrinePargyline may increase the hypertensive activities of Norepinephrine.
NortriptylinePargyline may increase the serotonergic activities of Nortriptyline.
ObinutuzumabPargyline may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Pargyline.
OctreotidePargyline may increase the hypoglycemic activities of Octreotide.
OlanzapinePargyline may increase the serotonergic activities of Olanzapine.
OlmesartanOlmesartan may increase the hypotensive activities of Pargyline.
OlodaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Olodaterol.
OmapatrilatOmapatrilat may increase the hypotensive activities of Pargyline.
OrciprenalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Orciprenaline.
OxprenololOxprenolol may increase the hypotensive activities of Pargyline.
OxycodoneThe risk or severity of adverse effects can be increased when Pargyline is combined with Oxycodone.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pargyline.
ParoxetinePargyline may increase the serotonergic activities of Paroxetine.
PasireotidePargyline may increase the hypoglycemic activities of Pasireotide.
PenbutololPenbutolol may increase the hypotensive activities of Pargyline.
PentamidinePargyline may increase the hypoglycemic activities of Pentamidine.
PentoliniumPentolinium may increase the hypotensive activities of Pargyline.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Pargyline.
PergolideThe metabolism of Pergolide can be decreased when combined with Pargyline.
PerindoprilPerindopril may increase the hypotensive activities of Pargyline.
PethidinePargyline may increase the serotonergic activities of Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Pargyline.
PheniprazinePheniprazine may increase the hypotensive activities of Pargyline.
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Pargyline.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Pargyline.
PhenterminePargyline may increase the hypertensive activities of Phentermine.
PhentolaminePhentolamine may increase the hypotensive activities of Pargyline.
PhenylephrinePargyline may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Pargyline is combined with Phenylpropanolamine.
PholcodinePholcodine may increase the serotonergic activities of Pargyline.
PinacidilPargyline may increase the hypotensive activities of Pinacidil.
PindololPindolol may increase the hypotensive activities of Pargyline.
PioglitazonePargyline may increase the hypoglycemic activities of Pioglitazone.
PirbuterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Pirbuterol.
PirlindolePirlindole may increase the hypotensive activities of Pargyline.
PivhydrazinePivhydrazine may increase the hypotensive activities of Pargyline.
PizotifenPargyline may increase the anticholinergic activities of Pizotifen.
PolythiazidePolythiazide may increase the hypotensive activities of Pargyline.
PramlintidePargyline may increase the hypoglycemic activities of Pramlintide.
PrazosinPrazosin may increase the hypotensive activities of Pargyline.
ProcaterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Procaterol.
PropranololPropranolol may increase the hypotensive activities of Pargyline.
ProtriptylinePargyline may increase the serotonergic activities of Protriptyline.
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Pargyline.
QuinaprilQuinapril may increase the hypotensive activities of Pargyline.
QuinineQuinine may increase the hypotensive activities of Pargyline.
QuininePargyline may increase the hypoglycemic activities of Quinine.
RamiprilRamipril may increase the hypotensive activities of Pargyline.
RasagilineRasagiline may increase the hypotensive activities of Pargyline.
RemikirenRemikiren may increase the hypotensive activities of Pargyline.
RepaglinidePargyline may increase the hypoglycemic activities of Repaglinide.
RescinnaminePargyline may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Pargyline.
RiociguatPargyline may increase the hypotensive activities of Riociguat.
RitodrineThe risk or severity of adverse effects can be increased when Pargyline is combined with Ritodrine.
RituximabPargyline may increase the hypotensive activities of Rituximab.
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Pargyline.
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Pargyline.
RosiglitazonePargyline may increase the hypoglycemic activities of Rosiglitazone.
SafrazineSafrazine may increase the hypotensive activities of Pargyline.
SalbutamolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salbutamol.
SalmeterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Salmeterol.
SaprisartanSaprisartan may increase the hypotensive activities of Pargyline.
SaxagliptinPargyline may increase the hypoglycemic activities of Saxagliptin.
SelegilineSelegiline may increase the hypotensive activities of Pargyline.
SelexipagPargyline may increase the hypotensive activities of Selexipag.
SertralinePargyline may increase the serotonergic activities of Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Pargyline.
SitagliptinPargyline may increase the hypoglycemic activities of Sitagliptin.
SitaxentanPargyline may increase the hypotensive activities of Sitaxentan.
SpiraprilSpirapril may increase the hypotensive activities of Pargyline.
SulfadiazinePargyline may increase the hypoglycemic activities of Sulfadiazine.
SulfamethoxazolePargyline may increase the hypoglycemic activities of Sulfamethoxazole.
SulfisoxazolePargyline may increase the hypoglycemic activities of Sulfisoxazole.
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Pargyline.
SunitinibPargyline may increase the hypoglycemic activities of Sunitinib.
TadalafilTadalafil may increase the antihypertensive activities of Pargyline.
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pargyline.
TelmisartanTelmisartan may increase the hypotensive activities of Pargyline.
TemocaprilPargyline may increase the hypotensive activities of Temocapril.
TerbutalineThe risk or severity of adverse effects can be increased when Pargyline is combined with Terbutaline.
TerlipressinPargyline may increase the hypotensive activities of Terlipressin.
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Pargyline.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pargyline.
TetryzolinePargyline may increase the hypertensive activities of Tetryzoline.
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Pargyline.
TianeptinePargyline may increase the serotonergic activities of Tianeptine.
TibolonePargyline may increase the hypotensive activities of Tibolone.
TicrynafenPargyline may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Pargyline.
TolazamidePargyline may increase the hypoglycemic activities of Tolazamide.
TolazolineTolazoline may increase the hypotensive activities of Pargyline.
TolbutamidePargyline may increase the hypoglycemic activities of Tolbutamide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pargyline.
ToloxatoneToloxatone may increase the hypotensive activities of Pargyline.
TorasemideTorasemide may increase the hypotensive activities of Pargyline.
TramadolTramadol may increase the neuroexcitatory activities of Pargyline.
TrandolaprilTrandolapril may increase the hypotensive activities of Pargyline.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Pargyline.
TranylcypromineTranylcypromine may increase the hypotensive activities of Pargyline.
TravoprostTravoprost may increase the hypotensive activities of Pargyline.
TrazodonePargyline may increase the serotonergic activities of Trazodone.
TreprostinilTreprostinil may increase the hypotensive activities of Pargyline.
TrichlormethiazideTrichlormethiazide may increase the hypotensive activities of Pargyline.
TrimazosinPargyline may increase the hypotensive activities of Trimazosin.
TrimethaphanTrimethaphan may increase the hypotensive activities of Pargyline.
TrimipraminePargyline may increase the serotonergic activities of Trimipramine.
UdenafilUdenafil may increase the antihypertensive activities of Pargyline.
UnoprostonePargyline may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Pargyline.
VardenafilVardenafil may increase the antihypertensive activities of Pargyline.
VenlafaxinePargyline may increase the serotonergic activities of Venlafaxine.
VilanterolThe risk or severity of adverse effects can be increased when Pargyline is combined with Vilanterol.
VilazodonePargyline may increase the serotonergic activities of Vilazodone.
VortioxetinePargyline may increase the serotonergic activities of Vortioxetine.
XylometazolinePargyline may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Pargyline.
ZimelidinePargyline may increase the serotonergic activities of Zimelidine.
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Pargyline.
Food Interactions
  • Food increases the oral bioavailability by 3-5 fold.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Primary amine oxidase activity
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine.
Gene Name:
MAOB
Uniprot ID:
P27338
Molecular Weight:
58762.475 Da
References
  1. Chrisp P, Mammen GJ, Sorkin EM: Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease. Drugs Aging. 1991 May;1(3):228-48. [PubMed:1794016 ]
  2. Heinonen EH, Myllyla V: Safety of selegiline (deprenyl) in the treatment of Parkinson's disease. Drug Saf. 1998 Jul;19(1):11-22. [PubMed:9673855 ]
  3. Authors unspecified: Selegiline: a second look. Six years later: too risky in Parkinson's disease. Prescrire Int. 2002 Aug;11(60):108-11. [PubMed:12199263 ]
  4. Macleod AD, Counsell CE, Ives N, Stowe R: Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD004898. [PubMed:16034956 ]
  5. Magyar K, Tothfalusi L: Pharmacokinetic aspects of deprenyl effects. Pol J Pharmacol Pharm. 1984 Jul-Aug;36(4):373-84. [PubMed:6441926 ]
  6. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. [PubMed:7995016 ]
  7. Deleu D, Northway MG, Hanssens Y: Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet. 2002;41(4):261-309. [PubMed:11978145 ]
  8. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  9. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  10. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  11. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
  12. Villeneuve C, Caudrillier A, Ordener C, Pizzinat N, Parini A, Mialet-Perez J: Dose-dependent activation of distinct hypertrophic pathways by serotonin in cardiac cells. Am J Physiol Heart Circ Physiol. 2009 Aug;297(2):H821-8. doi: 10.1152/ajpheart.00345.2009. Epub 2009 Jun 19. [PubMed:19542488 ]
  13. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
  14. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Serotonin binding
Specific Function:
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine.
Gene Name:
MAOA
Uniprot ID:
P21397
Molecular Weight:
59681.27 Da
References
  1. Patkar AA, Pae CU, Masand PS: Transdermal selegiline: the new generation of monoamine oxidase inhibitors. CNS Spectr. 2006 May;11(5):363-75. [PubMed:16641841 ]
  2. Azzaro AJ, Ziemniak J, Kemper E, Campbell BJ, VanDenBerg C: Pharmacokinetics and absolute bioavailability of selegiline following treatment of healthy subjects with the selegiline transdermal system (6 mg/24 h): a comparison with oral selegiline capsules. J Clin Pharmacol. 2007 Oct;47(10):1256-67. Epub 2007 Aug 22. [PubMed:17715422 ]
  3. Lee KC, Chen JJ: Transdermal selegiline for the treatment of major depressive disorder. Neuropsychiatr Dis Treat. 2007;3(5):527-37. [PubMed:19300583 ]
  4. Baker GB, Sowa B, Todd KG: Amine oxidases and their inhibitors: what can they tell us about neuroprotection and the development of drugs for neuropsychiatric disorders? J Psychiatry Neurosci. 2007 Sep;32(5):313-5. [PubMed:17823646 ]
  5. Murphy DL, Karoum F, Pickar D, Cohen RM, Lipper S, Mellow AM, Tariot PN, Sunderland T: Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). J Neural Transm Suppl. 1998;52:39-48. [PubMed:9564606 ]
  6. Fuentes JA, Ordaz A, Neff NH: Central mediation of the antihypertensive effect of pargyline in spontaneously hypertensive rats. Eur J Pharmacol. 1979 Jul 15;57(1):21-7. [PubMed:477738 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 15:04 / Updated on August 17, 2016 12:23